Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Interferon combined with ribavirin treatment is effective for children with chronic Hepatitis C virus

Interferon combined with ribavirin treatment is effective for children with chronic Hepatitis C virus

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Protocol used to treat the first known survivor of rabies without prior vaccination published

Protocol used to treat the first known survivor of rabies without prior vaccination published

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Milk thistle not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease

Milk thistle not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease

Small number of genes can predict response to chronic hepatitis C therapy

Small number of genes can predict response to chronic hepatitis C therapy

Respiratory syncytial virus affects the elderly and high-risk adults as much as influenza

Respiratory syncytial virus affects the elderly and high-risk adults as much as influenza

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

New approaches for the treatment of chronic hepatitis C

New approaches for the treatment of chronic hepatitis C

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Respiratory therapists are at an increased risk of developing asthma

Respiratory therapists are at an increased risk of developing asthma

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Lassa Fever, not seen in US for 15 years re-emerges

Lassa Fever, not seen in US for 15 years re-emerges

Neck surgeons brush up on West Nile virus

Neck surgeons brush up on West Nile virus

Widely used antimalarial drug exhibits antiviral activity against the SARS

Widely used antimalarial drug exhibits antiviral activity against the SARS

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

New drug combination more effective than the previous generation of hepatitis C/HIV therapy